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Introduction
Breast cancer, the neoplasm with the highest incidence world-
wide, is the most frequent cause of cancer-related death in women. 
Fortunately, its mortality has been regressive since the 1970s, but 
still more than half a million women died from breast cancer and 
its consequences in 2011.
The main reason for death is seldom the primary tumor itself 
but the overall tumor mass, due to the occurrence of remote metas-
tases in other organs. The so-called circulating tumor cells (CTCs) 
are considered to be at the root of metastatic lesions. It is well 
known that CTCs are cells that dissociate from a primary tumor, 
move into the circulation through invasion of blood or lymphatic 
vessels, settle down at secondary sites in the body and can there 
become the origin of metastasis formation [1–4]. A number of 
clinical studies were published showing that the presence of CTCs 
in the blood of cancer patients is correlated with poor outcome of 
the disease [5–7] and a worse prognosis for overall survival in com-
parison to patients without CTCs [8–10]. In light of this, CTCs are 
already used as tumor markers [11].
Different techniques for CTC detection from blood samples 
have already been established [12]. It has already been shown, that 
real-time polymerase chain reaction (PCR) is a high-throughput 
method for detection and molecular characterization of CTCs [13–
15], which also allows the monitoring of treatment efficiency 
[16–19].
The detection of CTCs via real-time quantitative PCR (RT-
qPCR) is based on the fact that tumor cells are of epithelial origin, 
assuming that blood samples with CTCs would show higher ex-
pression levels of typical epithelial genes than blood samples with-
out CTCs [20]. Our research group has already worked on the 
topic of CTC detection from blood samples [21]. We were able to 
establish and validate this method in an in vitro model system [22, 
23]. The present study is now the extension of our former work by 
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Summary
Background: Circulating tumor cells (CTCs) are cells that 
detach from a primary tumor, circulate through the 
blood stream and lymphatic vessels, and are considered 
to be the main reason for remote metastasis. Due to 
their origin, tumor cells have different gene expression 
levels than the surrounding blood cells. Therefore, they 
might be detectable in blood samples from breast cancer 
patients by real-time quantitative polymerase chain reac-
tion (RT-qPCR). Materials and Methods: Blood samples 
of healthy donors and adjuvant breast cancer patients 
were withdrawn and the cell fraction containing white 
blood cells and tumor cells was enriched by density gra-
dient centrifugation. RNA was isolated and reverse tran-
scribed to cDNA, which was then used in TaqMan real-
time PCR against cytokeratin (CK)8, CK18 and CK19. 18S 
and GAPDH were used as controls. Results: All 3 CKs 
were, on average, found to be significantly higher ex-
pressed in adjuvant breast cancer samples compared to 
negative controls, probably due to the presence of CTCs. 
Unfortunately, gene expression levels could not be cor-
related to tumor characteristics. Conclusions: RT-qPCR 
could make up a new approach for the detection of CTCs 
from blood samples of breast cancer patients, but a cor-
relation of the PCR data to gold standard methods in 
CTC detection would help to further improve the inform-
ative value of the qPCR results.
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moving from the model system towards patient samples, focusing 
on the possibility to detect CTCs in blood samples of adjuvant 
breast cancer patients to obtain hints on the clinical significance of 
this method.
For this purpose, blood samples from healthy donors and breast 
cancer patients in the adjuvant setting were analyzed by RT-qPCR. 
For that purpose we used standardized gene expression values of 
cytokeratin (CK)8, CK18, and CK19. We selected these cytokeratin 
genes as markers since their proteins are also in use as tumor cell 
markers in the alkaline phosphatase-antialkaline phosphatase 
(APAAP) staining [24, 25], a routine detection method for tumor 
cells.
We found an increase in the expression levels of all 3 CK genes 
in the adjuvant patient group in comparison to the healthy control 
group, which was statistically significant. Unfortunately, the gene 
expression values could not be related to tumor characteristics, so 
that a comparison of the RT-qPCR results with gold standard 




From each of 20 breast cancer patients, 20 ml blood was withdrawn during 
primary breast-conserving surgery by using rather fine concave needles, to 
avoid epithelial cells from the skin to enter the circulation. These patients were 
treated consecutively with adjuvant breast cancer therapy. Written consent of 
the patients was obtained prior to the procedure (ethical votum LMU 148–12, 
in accordance with the Declaration of Helsinki). 20 ml blood was also obtained 
from each of 20 healthy female donors who had no surgical interventions or 
previous biopsies before blood withdrawal.
The white blood cell fraction, potentially containing CTCs, was enriched by 
density gradient centrifugation with Histopaque (Invitrogen, Darmstadt, Ger-
many) for 30 min at 400 × g. Harvested cell pellets were washed twice at 250 × 
g, 4 ° C for 10 min with phosphate-buffered saline (PBS; Biochrom, Berlin, Ger-
many) and stored at –80 ° C until further sample processing.
RNA Isolation
RNA was extracted from the cell pellets by the Trizol (Invitrogen, Darm-
stadt, Germany)/chloroform (Merck, Darmstadt, Germany) extraction method 
and resuspended in diethylpyrocarbonate (DEPC)-treated water. RNA concen-
trations and ratios were determined photometrically (Nanodrop, Implen, Mu-
nich, Germany), while RNA integrity was controlled by performing denaturing 
formaldehyde gel electrophoresis.
Reverse Transcription
Of the isolated total RNA, 4 μg was used for cDNA generation by the Super-
Script III First Strand Synthesis Super Mix Kit (Invitrogen, Darmstadt, Ger-
many). Reactions were set up and run according to the manufacturer’s instruc-
tions; thereafter, samples were kept at –20 ° C until use in RT-qPCR.
RT-qPCR
RT-qPCR reactions were performed on 96-well plates (Micro Amp® Fast 
Optical 96-well reaction plate with barcode; ABI, Foster City, CA, USA). For 
each reaction, 2 μl of the respective cDNA was used, and a reaction mix con-
taining TaqMan® Fast Universal Mastermix (ABI, Foster City, CA, USA), H2O, 
and the respective TaqMan® hydrolysis probe (ABI, Foster City, CA, USA; 
CK8: Hs_02339472_g1, CK18: Hs_01920599_gH, CK19: Hs_00761767_g1, 18S: 
Hs_03928990_g1, GAPDH: Hs_00266705_g1) was added. Plates were run in 
Fig. 1. Comparison of average RQ values from samples of healthy donors ver-
sus adjuvant breast cancer samples. (a) CK8, (b) CK18, (c) CK19. In all three 








the 7500 Fast Real Time PCR system. 18S (coding for the 18S ribosomal pro-
tein) and GAPDH (coding for glyceraldehyde 3-phospate dehydrogenase) were 
included as reference genes. Reactions for every gene were always set up as 
quadruplicates including non-template and no-reverse transcription controls; 
the PCR efficiency of the hydrolysis probes used was stated as 100 ± 10% by the 
provider, and was therefore not controlled again.
Evaluation
The fluorescence signals were evaluated with the Applied Biosystems Se-
quence Detection Software (SDS v1.3.1), and CT (cycle threshold), ΔCT, ΔΔCT, 
and RQ (relative expression) values were automatically calculated according to 
the 2–ΔΔCT method [26]. Non-template and –RT controls did not yield any fluo-
rescent signals.
SDS-generated files were transferred to Microsoft© ExcelTM and corre-
sponding graphs were created. Statistical evaluations were done by SPSS v.20, 
using one-way ANOVA to compare the gene expression levels of sample 
groups.
Results
Gene expression values of CK8, CK18 and CK19 were standard-
ized to 18S and GAPDH, and average gene expression values were 
compared between the healthy control group and the adjuvant 
breast cancer patients (fig. 1a—c, table 1). For CK8, the average RQ 
value in the control group was 4.95, while in the group of adjuvant 
breast cancer patients, the value was 59.607. We detected the same 
trend for CK18 and CK19: For CK18, the averaged value of the 
healthy control group was 4.151 and the patient group value was 
33.539; and for CK19, the average values were 116.297 and 952.937, 
respectively. This corresponds to a 12-fold difference in gene ex-





Negative controls,  
average (SD)
Adjuvant breast cancer  
samples, average (SD)
CK8  4.95 (13.807)  59.607 (128.609) 0.047
CK18  4.151 (6.918)  33.539 (66.957) 0.041
CK19 116.297 (176.702) 952.937 (1826.096) 0.057
For the adjuvant breast cancer samples, the RQ values are significantly higher 
(indicated by the p-value) than for the negative control samples, indicating the 
presence of CTCs.
RQ = Relative expression, SD = standard deviation, CK = cytokeratin.
Fig. 2. Fold differences in RQ values between adjuvant breast cancer samples 
and negative control samples. The most prominent difference is seen for CK8.
Table 2. Correlation of tumor characteristics and RQ values for CK8, CK18, and CK19
No. T stage Size, mm N stage Histology Age ER status PR status HER2 status RQ CK8 RQ CK18 RQ CK19
 1 pT1b 11 pN1a (1/2) inv. duct 58 neg. neg. n.d.   7.471   3.272  102.127
 2 cT2 27 n.d. inv. duct 39 n.d. n.d. n.d.   3.349   1.528   32.533
 3 pT1c 19 pN0 (0/1) inv. duct 52 neg. neg. pos.   0.901   0.32   28.47
 4 pT1c 12 pN1a (1/14) inv. duct 73 pos. pos. neg.   3.126   2.639  185.744
 5 pT1b  6 pN0 (0/3) inv. duct 66 pos. pos. pos.   0.306   0.185   14
 6 pT1c 12 pN0 (0/2) inv. duct 66 pos. pos. neg. 203.192 117.464 3338.293
 7 pT2 25 pN0 (0/1) inv. duct 70 pos. pos. pos.  63.171  46.598 1269.884
 8 pT1c 13 pN0 (0/2) inv. duct 70 pos. pos. pos.  n.d.  n.d.   n.d.
 9 pT2 30 pN0 (0/3) inv. duct 46 pos. pos. pos.   1.432   0.806   21.22
10 pT2 22 pN0 (0/1) inv. duct 48 pos. pos. neg.   5.576   3.424  103.026
11 pT1c 18 pN0 (0/2) inv. duct 63 pos. pos. neg.   0.075   0.054    1.873
12 cT3 55 pN0 (0/2) inv. duct 53 neg. neg. neg.   0.105   0.121    1.259
13 pT1c 12 pN0 (0/2) inv. duct 52 pos. pos. pos.   1.89   1.019   72.961
14 pT2 25 pN0 (0/7) inv. lob 63 pos. pos. pos.   1.629   1.786   52.762
15 pT1c 13 pN0 (0/1) inv. duct 70 pos. pos. pos.   0.407   0.634   17.851
16 pT2 40 pN0 (0/5) inv. duct 70 pos. pos. pos. 155.595 135.514 4635.474
17 pT1c 20 pN0 (0/1) inv. duct 71 neg. neg. neg.   6.834   4.656  106.96
18 pT1c 15 pN0 (0/1) inv. duct 51 pos. pos. neg. 402.414 173.955 6310.456
19 pT1c 18 pN0 (0/4) inv. duct 50 pos. neg. pos.   2.911   2.64   41.437
20 pT1c/pT1b 12/9 pN0 (0/1) inv. duct 70 pos./pos. pos./pos. pos./neg. 273.943 142.751 1769.476
No correlation between tumor data and RQ values could be shown. For patients 3, 5, 11, 12, and 15, a downward deviation of the RQ values from the average RQ 
value is seen; in patients 6, 7, 16, 18, and 20, the RQ values deviate upwards from the average RQ.
ER = Estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor, RQ = relative expression, CK = cytokeratin, n.d. = not  
detectable, inv. duct = invasive ductal, inv. lob = invasive lobular, neg. = negative, pos. = positive.
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pression for CK8 and an 8-fold difference between the 2 sample 
groups for CK18 and CK19 (fig. 2).
For statistical analysis, a t-test on independent samples was ap-
plied to the data. The test yielded statistically significant differences 
in gene expression levels for CK8 (p = 0.047) and CK18 (p = 0.041). 
For CK19, a borderline significance was detected (p = 0.057) 
(table 1).
Combination of the RQ values of each patient sample and the 
respective patient and tumor data did not result in any significant 
correlation (table 2, also for standard deviations).
Discussion
RT-qPCR seems to be a promising method for CTC detection in 
blood samples [5–7, 13–15] of patients suffering from different 
types of cancer, such as breast cancer, for example. But still a lot of 
work needs to be done. As the on-hand preliminary study shows, 
the presence of tumor cells in blood samples can indeed be de-
tected but the number of CTCs [27] cannot yet be quantified with 
reference to the used technique. To overcome this limitation, 
standard curves have to be generated to be able to correlate gene 
expression levels to the number of CTCs contained in a certain 
blood sample. However, as different types of breast cancer express 
different genes at different levels, the creation of reliable standard 
curves will be a challenging task. Another drawback of the method-
ology is that it cannot be completely avoided that, by blood with-
drawal or previous therapeutical interventions, single epithelial 
cells will enter the circulation and are later detected as CTCs, as it 
was shown in a number of publications [28–30], resulting in false-
positive outcomes. Although using similar detection methods, 
other research groups did not find epithelial cells in blood samples 
of healthy control persons [31, 32]. Therefore it could be generally 
concluded that sample withdrawal has to be carried out with care, 
so that the number of such false-positive cells is kept rather small, 
e.g. by using fine butterfly needles for blood extraction. An analysis 
of the samples by ancillary methods would help to overcome this 
obstacle [33].
In the following, a simultaneous analysis of blood samples by 
RT-qPCR and a gold standard method, the CellSearchTM system, 
could on the one hand help to generate these standard curves and 
on the other hand might be useful for the correlation of patient/
tumor data and RQ values. Also, an analysis of blood from meta-
static patients could improve PCR-based detection of CTCs as the 
CTC incidence in this patient group is significantly higher, but 
bears the disadvantage that material from metastatic patients is 
rather rare. Another important and interesting point would be to 
decide by the RT-qPCR results whether a certain blood sample 
came from a cancer patient or was withdrawn from a healthy 
donor. But for this purpose, a lot of work still needs to be done, es-
pecially in defining a set of marker genes on which this decision 
could be made with high reliability [34–36]. The analysis of more 
marker genes like Her-2 [37], MMP13 [38], UBE2Q2 [39], or Nec-
tin-4 [40] for their use in CTC detection could help in this point, 
allowing a more sensitive detection with simultaneous characteri-
zation of the tumor cells as well. With the help of such a marker 
gene panel, an epithelial cell adhesion molecule (EPCAM)-inde-
pendent CTC detection method could be developed, meaning that 
the epithelial-to-mesenchymal transition (EMT; [41, 42]) would no 
longer influence the CTC detection. The latter could be regarded as 
a drawback of the present study as well. Thereby new roads to-
wards a more individualized treatment with increasing treatment 
efficiency and reduced therapeutic side effects could eventually be 
opened.
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